Education and Strategy Are Key to Nurturing Biosimilars for Success
FiercePharma
Heralded as the next great chapter in pharmaceutical history, biosimilars are expected to trim healthcare costs while giving patients more access at lower prices. Adopted with open arms in the European market, the move to biosimilars in the U.S. has been a slog.
Although first approved by the FDA in 2013, only 26 biosimilars have been given the regulatory agency’s nod and of those, only thirteen have been launched. Still, of those approvals, 18 occurred in the last two years. A sign that biosimilars have been gaining traction in the U.S.
“I’d say that it was a slow start but if we fast forward to today, we’re starting to see some momentum,” Sean McGowan, Senior Director of Biosimilars at AmerisourceBergen, said.
For the full article, check out FiercePharma.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.